FORMELA JEAN FRANCOIS 4

What Happened

• Formela Jean Francois, a director of Korro Bio (KRRO), sold a total of 109,023 shares in open‑market transactions between July 2 and July 6, 2026, generating gross proceeds of approximately $1,542,970. The sales were executed at weighted‑average prices around $13.96–$14.03 (individual trades ranged $13.95–$14.16).
• These transactions are sales (not purchases) and thus do not signal a buy-side vote of confidence; the filing notes that some of the sales were executed pursuant to a Rule 10b5‑1 trading plan.

Key Details

• Transaction dates and reported disposals:
  • 2026-07-02: 85,955 shares sold at $14.03 (≈ $1,205,949)
  • 2026-07-02: 14,745 shares sold at $14.03 (≈ $206,872)
  • 2026-07-06: 817 shares sold at $13.96 (≈ $11,405)
  • 2026-07-06: 8,506 shares sold at $13.96 (≈ $118,744)
• Total shares sold: 109,023; total gross proceeds: ≈ $1,542,970.
• Footnotes of note:
  • F1: Some sales were made under a Rule 10b5‑1 trading plan adopted April 8, 2026.
  • F2/F5: Reported prices are weighted averages; trades occurred across price ranges $13.95–$14.16 and $13.95–$14.05 respectively. The filer can provide per‑price breakdown on request as noted in the filing.
  • F3/F4: The filing also contains footnotes referencing shares held by Atlas venture funds and related beneficial‑ownership disclaimers.
• Shares owned after transaction: Not specified in the provided filing.
• Timeliness: Trades dated July 2 were reported on July 7 (filed one business day late); trades dated July 6 were filed timely.

Context

• These were outright open‑market sales (code S). Because some sales occurred under a 10b5‑1 plan, they may have been pre‑scheduled and are often routine; the filing itself does not state the insider’s motivation.
• For retail investors: purchases are typically more informative about insider conviction; routine, plan‑based sales are common and can reflect diversification or liquidity needs rather than negative company news.